结论:异基因造血干细胞移植是目前治愈bcr/abl融合基因阳性急性白血病的惟一有效手段,联合酪氨酸激酶抑制剂能有效提高长期生存率.%Aim:To observe the effect of allogeneic hematopoietic stem cell transplantation (AHSCT) on acute leukemia with bcr/abl fusion gene-positive.Methods: A total of 18 ...
Thus, the burning question is: to what extent 'Does TKI treatment in CP CML suppress or just significantly is BCR-ABL1 kinase activity the cause of the GI? delay its transformation into a classical Ph-positive or worse, a BCR-ABL1 kinase increases the levels of reactive oxygen Ph-negative...
CGP57148B also inhibited constitutively active Akt kinase and NFκB in Bcr-Abl–positive cells. Attenuation of NFκB activity by ectopic expression of transdominant repressor of IκB sensitized HL-60/Bcr-Abl and K562 cells to TNF-α but not to apoptosis induced by Ara-C or doxorubicin. ...
J Vormoor2,3, O Ottmann6, A Ganser1, A Pich5, D Hilfiker-Kleiner4, O Heidenreich2 and M Eder1 Despite advances in allogeneic stem cell transplantation, BCR-ABL-positive acute lymphoblastic leukaemia (ALL) remains a high-risk disease, necessitating the development of novel treatment strategies...
Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. Clin Cancer Res. 2009;15:3442–50. Article CAS PubMed Google Scholar Kuntz EM, Baquero P, Michie AM, Dunn K, Tardito S, Holyoake TL, et al. Targeting mitochondrial oxidative phosphorylation ...
After the discovery of the Ph chromosome, it was demonstrated that between 20% and 30% of patients with acute lymphoblastic leukemia (ALL) are also BCR-ABL1-positive (Ph+ ALL). These patients are typically older, have an increased risk of disease involving the central nervous system, and ha...
The roles of the JAK/STAT, Raf/MEK/ERK and PI3K/Akt signal transduction pathways and the BCR-ABL oncoprotein in leukemogenesis and their importance in the regulation of cell cycle progression and apoptosis are discussed in this review. These pathways hav
In the present study we demonstrate that MYC and its partner MAX bind to the BCR promoter, leading to up-regulation of BCR and BCR/ABL1 at both transcriptional and protein levels. Accordingly, silencing of MYC expression in various BCR/ABL1 positive cell lines causes significant downregulation ...
This therapeutic agent is used to treat Philadelphia chromosome-positive (Ph+) CML as well as Imatinib-resistant CML. Nilotinib is a highly potent antineoplastic agent characterized by its oral bioavailability and ability to act as an inhibitor of Bcr-Abl tyrosine kinase [40]. With a s...
The assay detected 1 B-cell receptor–ABL-positive cell in 100 000 cells, as determined by dilution experiments with CML cells in normal controls. In the case of quantitative PCR negativity, nested PCR with a sensitivity of approximately 1 to 5 × 1:106 was performed as previously described....